Bio-Connect
IHC-P analysis of human breast carcinoma tissue using GTX86939 Factor VII (cleaved Arg212) antibody. The picture on the right is blocked with the synthesized peptide.
IHC-P analysis of human breast carcinoma tissue using GTX86939 Factor VII (cleaved Arg212) antibody. The picture on the right is blocked with the synthesized peptide.
IHC-P analysis of human breast carcinoma tissue using GTX86939 Factor VII (cleaved Arg212) antibody. The picture on the right is blocked with the synthesized peptide.

Factor VII (cleaved Arg212) antibody

GTX86939
GeneTex
ApplicationsWestern Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
ReactivityHuman
TargetF7
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    GeneTex
  • Product Name
    Factor VII (cleaved Arg212) antibody
  • Delivery Days Customer
    9
  • Antibody Specificity
    Factor VII (cleaved Arg212) antibody detects endogenous levels of fragment of activated FA7 resulting from cleavage adjacent to Arg212.
  • Application Supplier Note
    WB: 1:500~1:1000. IHC-P: 1:50~1:100. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
  • Applications
    Western Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
  • Certification
    Research Use Only
  • Clonality
    Polyclonal
  • Conjugate
    Unconjugated
  • Gene ID2155
  • Target name
    F7
  • Target description
    coagulation factor VII
  • Target synonyms
    coagulation factor VII; coagulation factor VII (serum prothrombin conversion accelerator); eptacog alfa; FVII coagulation protein; proconvertin; SPCA
  • Host
    Rabbit
  • Isotype
    IgG
  • Protein IDP08709
  • Protein Name
    Coagulation factor VII
  • Scientific Description
    This gene encodes coagulation factor VII which is a vitamin K-dependent factor essential for hemostasis. This factor circulates in the blood in a zymogen form, and is converted to an active form by either factor IXa, factor Xa, factor XIIa, or thrombin by minor proteolysis. Upon activation of the factor VII, a heavy chain containing a catalytic domain and a light chain containing 2 EGF-like domains are generated, and two chains are held together by a disulfide bond. In the presence of factor III and calcium ions, the activated factor then further activates the coagulation cascade by converting factor IX to factor IXa and/or factor X to factor Xa. Defects in this gene can cause coagulopathy. Alternative splicing results in multiple transcript variants encoding different isoforms that may undergo similar proteolytic processing to generate mature polypeptides. [provided by RefSeq, Aug 2015]
  • Reactivity
    Human
  • Storage Instruction
    -20°C or -80°C,2°C to 8°C
  • UNSPSC
    12352203